Taiwan Biomaterial Co., Ltd. (6649.TWO) Stock
Taiwan Biomaterial Co., Ltd.

Company profile
Taiwan Biomaterial reported revenue of 220.40 million TWD for fiscal year 2025. Our analysis of its filings shows revenue growing from 72.84 million TWD in fiscal year 2023 to 220.40 million TWD in fiscal year 2025, 74.0% a year on average. Taiwan Biomaterial reports about 46 full-time employees.
What stands out
- Revenue more than doubled (up 128.2%) in fiscal year 2025, from 96.57 million TWD in fiscal year 2024, after a rise of 32.6% the year before.
- It returned to a profit in fiscal year 2025, 58.93 million TWD, after 2 years of net losses (1.73 million TWD in fiscal year 2024).
- The United States brought in 99% of revenue by region in fiscal year 2025, up from 93% in fiscal year 2024; the company is based in Taiwan.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Taiwan Biomaterial Co., Ltd.
Taiwan Biomaterial Co., Ltd. engages in the development and sale of implantable medical devices in Taiwan. It provides Foamagen, a foamagen dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and nickel-titanium guidewire for guiding cerebral vascular surgery; tissue repair and regeneration products for the treatment of early osteoarthritis; and CDMO. The company was founded in 1921 and is based in Zhubei, Taiwan.
Leadership
- Derek Ma — General Manager
- Yun Quan Li — Accounting Supervisor
How much revenue does Taiwan Biomaterial make?
Taiwan Biomaterial reported 220.40 million TWD in revenue for fiscal year 2025, up 128.2% from 96.57 million TWD in fiscal year 2024.
Where does Taiwan Biomaterial make most of its revenue?
United States: 99% of revenue by region in fiscal year 2025, followed by Taiwan (1%).
What companies are similar to Taiwan Biomaterial?
Listed companies of a similar size in the same industry (targeted healthcare equipment) include Icares Medicus, Inc. (6612.TWO), Crystalvue Medical Corporation (6527.TWO), Medimaging Integrated Solution Inc. (6796.TW), NaviFUS Corp. (6872.TWO).
How has Taiwan Biomaterial's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 41.67 million TWD; FY2022, 127.31 million TWD; FY2023, 72.84 million TWD; FY2024, 96.57 million TWD; FY2025, 220.40 million TWD.
Has Taiwan Biomaterial made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 47.44 million TWD; FY2022, 33.76 million TWD; FY2023, a loss of 10.13 million TWD; FY2024, a loss of 1.73 million TWD; FY2025, 58.93 million TWD. It reported a net loss in 3 of these 5 years.
Company Information
Data as of .
How to cite: DataPorium, “Taiwan Biomaterial Co., Ltd. (6649.TWO)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/6649.TWO